Health-Related Quality Of Life After Apalutamide Treatment In Patients with Metastatic Castration-Sensitive Prostate Cancer (TITAN): A Randomised, Placebo-Controlled, Phase 3 Study

Background: In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. We aimed to assess health-related quality of life (HRQOL) in TITAN, including pain and fatigue.

Methods: In this randomised, placebo-controlled, double-blind, phase 3 study, patients with metastatic castration-sensitive prostate cancer (defined as not receiving ADT at the time of metastatic disease progression) aged 18 years and older, receiving continuous ADT (selected at the investigator's discretion), and with an Eastern Cooperative Oncology Group performance status score of 0 or 1 were randomly assigned (1:1), using an interactive web response system, to receive oral apalutamide (four 60 mg tablets, once daily) or matching placebo. Previous localised disease treatment or previous docetaxel for metastatic castration-sensitive prostate cancer were allowed. Randomisation was stratified by Gleason score at diagnosis, region, and previous docetaxel treatment. Randomisation was done using randomly permuted blocks (block size of four). Investigators, research staff, sponsor study team, and patients were masked to the identities of test and control treatments. Patient-reported outcomes were prespecified exploratory endpoints and were the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and EuroQoL 5D questionnaire 5 level (EQ-5D-5L). BPI and BFI were completed for 7 consecutive days (days −6 to 1 inclusive of each cycle visit), then at months 4, 8, and 12 in follow-up. FACT-P and EQ-5D-5L were completed during cycles 1–7, then every other cycle until the end of treatment, and at months 4, 8, and 12 in follow-up. Analyses were based on the intention-to-treat population. Missing patient-reported outcome assessments were calculated as the expected number of assessments for a visit minus the actual number of assessments received for that visit. For time-to-event endpoints, when median values could not be calculated because less than 50% of patients had degradation, 25th percentiles were compared. This study is registered with, number NCT02489318, and is ongoing.

Findings: Between Dec 9, 2015, and July 25, 2017, 1052 eligible patients were enrolled randomly assigned to apalutamide (n=525) or placebo (n=527). Data cutoff for this analysis of patient-reported outcomes was Nov 23, 2018. Median follow-up for time to pain-related endpoints ranged from 19·4 to 22·1 months. Patients were mostly asymptomatic at baseline: on the BPI-SF pain severity scale of 0–10, median pain scores (indicating worst pain in the past 24 h) were 1·14 (IQR 0–3·17) in the apalutamide group and 1·00 (0–2·86) in the placebo group, and median worst fatigue scores on the BFI were 1·29 (IQR 0–3·29) in the apalutamide group and 1·43 (0·14–3·14) in the placebo group. Patient experience of pain and fatigue (intensity and interference) did not differ between the groups for the duration of treatment. Median time to worst pain intensity progression was 19·09 months (95% CI 11·04–not reached) in the apalutamide group versus 11·99 months (8·28–18·46) in the placebo group (HR 0·89 [95% CI 0·75–1·06]; p=0·20). Median time to pain interference progression was not reached in either group (95% CI 28·58–not reached in the apalutamide group; not reached–not reached in the placebo group). 25th percentiles for time to pain interference progression were 9·17 months (5·55–11·96) in the apalutamide group and 6·24 months (4·63–7·43) in the placebo group (HR 0·90 [95% CI 0·73–1·10]; p=0·29). FACT-P total scores and EQ-5D-5L data showed preservation of HRQOL in both groups. The median time to deterioration as determined by FACT-P total score was 8·87 months (95% CI 4·70–11·10) in the apalutamide group and 9·23 months (7·39–12·91) in the placebo group (HR 1·02 [95% CI 0·85–1·22]; p=0·85).

Interpretation: Apalutamide with ADT is a well-tolerated and effective option for men with metastatic castration-sensitive prostate cancer. The combination significantly improves survival outcomes compared with ADT alone while maintaining HRQOL despite additive androgen blockade. Funding Janssen Research & Development.

Authors: Prof Neeraj Agarwal, MD, Kelly McQuarrie, BSN, Prof Anders Bjartell, MD, Simon Chowdhury, MD, Andrea J Pereira de Santana Gomes, MD, Prof Byung Ha Chung, MD, Prof Mustafa Özgüroğlu, MD, Álvaro Juárez Soto, MD, Axel S Merseburger, MD, Prof Hirotsugu Uemura, MD, Prof Dingwei Ye, MD , Prof Robert Given, MD, Prof David Cella, PhD, Prof Ethan Basch, MD, Branko Miladinovic, PhD, Lindsay Dearden, MSc, Kris Deprince, MD, Vahid Naini, PharmD, Angela Lopez-Gitlitz, MD, Prof Kim N Chi, MD on behalf of the TITAN investigators

Clinical Trial Information: NCT02489318

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    CA Cancer J Clin. 2018; 68: 394-42
  2. Chen R, Ren S, Chinese Prostate Cancer Consortium, et al. Prostate cancer in Asia: a collaborative report. Asian J Urol. 2014; 1: 15-29
  3. National Cancer Institute Surveillance Epidemiology and End Results Program (SEER) Cancer stat facts: prostate cancer.
  4. Damodaran S, Lang JM, Jarrard DF Targeting metastatic hormone sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches. J Urol. 2019; 201: 876-885
  5. Katzenwadel A, Wolf P Androgen deprivation of prostate cancer: leading to a therapeutic dead end., Cancer Lett. 2015; 367: 12-17
  6. James ND Spears MR&nbsp Clarke NW et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015; 67: 1028-1038
  7. Johanes C&nbsp Monoarfa RA&nbsp Ismail RI&nbsp Umbas R Anxiety level of early- and late-stage prostate cancer patients. Prostate Int. 2013; 1: 177-182
  8. Clegg NJ  Wongvipat J&nbsp Joseph JD  et al.ARN-509: a novel antiandrogen for prostate cancer treatment.
  9. . US Food and Drug Administration FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. Medicines Agency
  10. Erleada (apalutamide). Date accessed: June 21, 2019
  11. Chi KN  Agarwal N  Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019; 381: 13-24
  12. Foucher Y  Lorent M  Tessier P  Supiot S  Sebille V Dantan E A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients. Health Qual Life Outcomes. 2018; 16: 40
  13. Aggarwal A Ginsburg O  Fojo T Cancer economics, policy and politics: what informs the debate? Perspectives from the EU, Canada and US. J Cancer Policy. 2014; 2: 1-11
  14. Morgans AK  Stockler MR Patient-reported outcomes in metastatic castration-sensitive prostate cancer in the adjuvant setting. Eur Urol Focus. 2019; 5: 144-146
  15. Turini M  Redaelli A  Gramegna P  Radice D Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics. 2003; 21: 527-541
  16. National Institute for Health and Care Excellence (NICE) Prostate cancer: diagnosis and management. Guidance NG131.
  17. Scher HI Halabi S Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159
  18. Cleeland CS Ryan KM Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23: 129-138
  19. Cleeland CS Brief pain inventory (short form).
  20. University of Texas MD Anderson Cancer Center Brief Fatigue Inventory Brief fatigue inventory. National Palliative Care Research Center.
  21. FACT Functional assessment of cancer therapy—prostate (version 4)
  22. Cella D Nichol MB Eton D Nelson JB Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009; 12: 124-129
  23. Esper P Mo F Chodak G Sinner M Cella D Pienta KJ Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997; 50: 920-9224.
  24. EuroQol Group EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument. Version 2.1.
  25. Herdman M Gudex C Lloyd A et al.Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).Qual Life Res. 2011; 20: 1727-1736
  26. Pearman TP Beaumont JL Mroczek D O'Connor M Cella D Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer. 2018; 124: 991-997
  27. Odedina FT Akinremi TO Chinegwundoh F et al. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009; 4: S2
  28. Scher HI Morris MJ Stadler WM et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34: 1402-1418

Go Beyond the Abstract and Read a Commentary by the Authors 

Source:Agarwal, Neeraj et al. 2019. "Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study". The Lancet Oncology. Elsevier BV. doi:10.1016/s1470-2045(19)30620-5.